Eplerenone is a mineralocorticoid receptor antagonist with minimal affinity for androgen receptors. Mineralocorticoid receptor antagonists are efficacious in the management of resistant hypertension, obstructive sleep apnea, cardiac dysfunction, renal tubular disorders, hepatic cirrhosis, portal hypertension, diabetic nephropathy, proteinuric kidney disease, and chronic central serous chorioretinopathy in the general population. Five cases describing the use of eplerenone in pregnancy are discussed, the previous literature reviewed, and potential indications for the use of eplerenone in pregnancy discussed.
HeckerAHasanSHNeumannF. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. Acta Endocrinol (Copenh)1980; 95: 540–545.
2.
SeassaroEPellegriniR. Experimental study on teratology of spironolactone. Quad Clin Ostet Ginecol1969; 24: 347–358.
3.
RoseLIRegesteinQRecklerJM. Lack of effect of spironolactone on male genital development. Invest Urol1975; 13: 95–96.
4.
ShahA. Ambiguous genitalia in a newborn with spironolactone exposure [abstract]. In: 93rd Annual Meeting of the Endocrine Society, Boston, June 6, 2011.
5.
AhmedSFHughesIA. The genetics of male undermasculinization. Clin Endocrinol (Oxf)2002; 56: 1–18.
6.
GrovesTDCorenblumB. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol1995; 172: 1655–1656.
7.
NeerhofMGShlossmanPAPollDS, et al.Idiopathic aldosteronism in pregnancy. Obstet Gynecol1991; 78: 489–491.
8.
de ArribaGSanchez-HerasMBasterrecheaMA. Gitelman syndrome during pregnancy: a therapeutic challenge. Arch Gynecol Obstet2009; 280: 807–809.
9.
RigoJ JrGlazEPappZ. Low or high doses of spironolactone for treatment of maternal Bartter’s syndrome. Am J Obstet Gynecol1996; 174: 97.
10.
DengNZhongJDengZ, et al.Case report: a pregnant woman accidental treated with spironolactone in mid-gestation. Front Pharmacol2024; 15: 1404251.
11.
InoueWMotokiHYoshieK, et al.Successful management of a pregnant patient with danon cardiomyopathy. Intern Med2024; 63: 681–686.
12.
CarrimMFMbelleMRabaliZ, et al.Non-cirrhotic portal hypertension in pregnancy due to schistosomiasis: a case series. Obstet Med2025; 18: 107–113.
13.
KerstenMHanckeKJanniW, et al.Pregnancy induced Cushing’s syndrome and primary aldosteronism: a case report. BMC Pregnancy Childbirth2020; 20: 21.
14.
RusavyZHudecAKarbanovaJ, et al.Gitelman syndrome in pregnancy—a severe hypokalemia with favorable perinatal prognosis. Ceska Gynekol2012; 77: 421–423.
15.
CrovettoFMoroniGZainaB, et al.Pregnancy in women with Alport syndrome. Int Urol Nephrol2013; 45: 1223–1227.
16.
StruthersAKrumHWilliamsGH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol2008; 31: 153–158.
17.
FlattDMBrownMCMizerackiAM, et al.Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review. JAMA Cardiol2016; 1: 607–612.
18.
KrasinskaBMiazgaACoftaS, et al.Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. Pol Arch Med Wewn2016; 126: 330–339.
19.
WuJPeiYWuJ, et al.Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord2025; 25: 01.
20.
IkedaAKMehraR. Obstructive sleep apnea and hypertension: is aldosterone blockade the optimal approach to control blood pressure and improve oxygenation?Curr Hypertens Rep2026; 28: 6.
21.
FarahMHHegaziMFirwanaM, et al.A systematic review supporting the Endocrine Society clinical practice guideline on management of primary aldosteronism. J Clin Endocrinol Metab2025; 110: e2833–e2844.
22.
SaitoJMitoAYakuwaN, et al.Eplerenone levels in maternal serum, cord blood, and breast milk during pregnancy and lactation. Hypertens Res2021; 44: 879–881.
23.
KananMAlshahraniRAlqahtaniA, et al.Exploring the clinical pharmackinetics of eplerenone: A systematic review of Pharmacy Practice(2025).
24.
ZhuYLiJHuangZ, et al.Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials. Ren Fail2026; 48: 2656561.
25.
MortonAPanitzBBushA. Eplerenone for gitelman syndrome in pregnancy. Nephrology (Carlton)2011; 16: 49.
26.
SimpsonFO. Combination therapy in hypertension. Drugs1980; 20: 69–73.
27.
MroczekWJLeibelBAFinnerty JrFA. Comparison of clonidine and methyldopa in hypertensive patients receiving a diuretic. A double-blind crossover study. Am J Cardiol1972; 29: 712–717.
28.
PutzeysMRHooblerSW. Comparison of clonidine and methyldopa on blood pressure and side effects in hypertensive patients. Am Heart J1972; 83: 464–468.
29.
SeedatYKVawdaEIMithaS, et al.A comparison of alpha-methyldopa (aldomet) and ST155 (catapres) in the treatment of hypertension. S Afr Med J1970; 44: 300–301.
30.
AmeryAVerstraeteMBossaertH, et al.Hypotensive action and side effects of clonidine-chlorthalidone and methyldopa-chlorthalidone in treatment of hypertension. Br Med J1970; 4: 392–395.
31.
KuokkanenKMattilaMJ. Antihypertensive effect of prazosin in combination with methyldopa, clonidine, or propranolol. Ann Clin Res1979; 11: 18–24.
32.
TurgeonRGarrisonSAllanGM. Three drugs and still hypertensive: what’s left?Can Fam Physician2016; 62: 904.
33.
GaddamKPimentaEThomasSJ, et al.Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens2010; 24: 532–537.
34.
YangLZhangHCaiM, et al.Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens2016; 38: 464–468.
35.
KrasinskaBCoftaSSzczepaniak-ChichelL, et al.The effects of eplerenone on the circadian blood pressure pattern and left ventricular hypertrophy in patients with obstructive sleep apnea and resistant hypertension-a randomized, controlled trial. J Clin Med2019; 8: 1–17. DOI:https://doi.org/10.3390/jcm8101671.
36.
SchwartzARHerpelLBoganR, et al.Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients. Sleep Breath2024; 28: 2571–2580. DOI: 10.1007/s11325-024-03113-1.
37.
De BackerJHaugaaKHHasselbergNE, et al.2025 ESC guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J2025; 46: 4462–4568.
38.
HutterDABerkowitzRDavisSEIII, et al.Application of continuous positive airway pressure in hypoxemic acute respiratory failure associated with diastolic dysfunction in pregnancy. Congest Heart Fail2006; 12: 174–175.
39.
MoustakakisMNBockornyM. Gitelman syndrome and pregnancy. Clin Kidney J2012; 5: 552–555.
40.
NajafiMSPNaderiN. Proximal weakness and hypokalemia in a pregnant woman: the first presentation of gitelman syndrome. Case Reports in Clinical Practice2020; 5: 30–34.
41.
LimMGannonD. Diagnosis and outpatient management of Gitelman syndrome from the first trimester of pregnancy. BMJ Case Rep2021; 14: 1–4. DOI: https://doi.org/10.1136/bcr-2021-241756.
42.
MortonALaurieJ. Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy. Pregnancy Hypertens2017; 7: 54–55.
43.
GehlertJMortonA. Eplerenone as a treatment for resistant hypertension in pregnancy. Obstet Med2021; 14: 35–38.
44.
CabassiARoccoRBerrettaR, et al.Eplerenone use in primary aldosteronism during pregnancy. Hypertension2012; 59: e18–e19.
45.
GunganahKCarpenterRDrakeWM. Eplerenone use in primary aldosteronism during pregnancy. Clin Case Rep2016; 4: 81–82.
46.
MangatKGKKissockJ. Primary hyperaldosteronism in a triplet pregnancy: considerations for intrapartum diagnosis and management. J Hypertens2023; 41: 1–1.
47.
BalachandranDMSubbaiahMDorairajanG. Primary aldosteronism during pregnancy and eplerenone use - a case report. Obstet Med2024; 17: 230–232.
48.
LinAChanSJCrapanzanoJP, et al.Severe hypokalaemia in primary aldosteronism during pregnancy. BMJ Case Rep2025; 18: 1–4. DOI: https://doi.org/10.1136/bcr-2024-262767.
49.
NewbiggingNSathyendraSJasmineS, et al.Hyperaldosteronism secondary to renal agenesis: an unusual cause for hypertension in pregnancy. Pregnancy Hypertens2024; 38: 101157.
50.
YoshiiTKanzakiHAoki-KamiyaC, et al.Multi-modal treatment in a pregnant woman with untreated cardiac sarcoidosis complicated by cardiac dysfunction and ventricular arrhythmias: a case report and literature review. Eur Heart J Case Rep2024; 8: ytae108.
51.
GavriilidisEAntoniadouCDimopoulouG, et al.First European case of geller syndrome complicated with hypokalemic nephropathy: a case report and literature review. Metabol Open2026; 29: 100429.
52.
DownieEShanmugalingamRHennessyA, et al.Assessment and management of primary aldosteronism in pregnancy: a case-control study. J Clin Endocrinol Metab2022; 107: e3152–e3158.
53.
LopezDRLManingat-GocoM. Use of eplerenone in primary aldosteronism during pregnancy: a case series. In: 22nd ASEAN Federation of Endocrine Societies Congress Bangkok, Thailand, 16-19th November 2023 2023, pp.1-1.
54.
SangaVRossittoGSecciaTM, et al.Management and outcomes of primary aldosteronism in pregnancy: a systematic review. Hypertension2022; 79: 1912–1921.
55.
AdlerGKStowasserMCorreaRR, et al.Primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab2025; 110: 2453–2495.
56.
FourkiotisVVonendODiederichS, et al.Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol2013; 168: 75–81.
57.
BuffoloFCavagliaGBurrelloJ, et al.Quality of life in primary aldosteronism: a prospective observational study. Eur J Clin Invest2021; 51: e13419.
58.
BlanchardAVargas-PoussouRValletM, et al.Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol2015; 26: 468–475.
59.
XuCBaoYDingH, et al.The association between antenatal indomethacin exposure and persistent pulmonary hypertension of the newborn in extremely preterm infants. Sci Rep2025; 15: 16962.
60.
D'AmbrosioVVenaFScopellitiA, et al.Use of non-steroidal anti-inflammatory drugs in pregnancy and oligohydramnios: a review. J Matern Fetal Neonatal Med2023; 36: 2253956.
61.
AlajjuriOASamahaMEHonemeyerU, et al.Balancing benefits and risks of indomethacin in the management of antenatal bartter syndrome: a case report. Front Med (Lausanne)2022; 9: 870503.
62.
FlorisMAngioiALeporiN, et al.The clinical spectrum of acquired hypomagnesemia: from etiology to therapeutic approaches. Biomedicines2025; 13: 1–24. DOI:https://doi.org/10.3390/biomedicines13081862.
63.
CinnamondKYDVargheseSCasserlyL. Pregnancy, primary aldosteronism and renal tubular disorders: a systematic review of the utility of amiloride in pregnancy. Nephrol Dial Transplant2025; 40: 1–13.
64.
ThadaniUJacobRG. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. Drugs Today (Barc)2008; 44: 925–937.
65.
AhmedMZulfiqarEHashmiTM, et al.Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. ESC Heart Fail2026; 13: 1–13. DOI:https://doi.org/10.1093/eschf/xvaf018.
66.
NaserNDurak-NalbanticASabanovic-BajramovicN, et al.The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF. Med Arch2023; 77: 105–111.
67.
HeidenreichPABozkurtBAguilarD, et al.2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation2022; 145: e876–e894.
BuffoloFVottaSGoiJ, et al.Screening of obstructive sleep apnea in patients with hypertension: review of the literature and results of an Italian survey. J Hypertens2026; 44: 233–242.
70.
PienGWPackAIJacksonN, et al.Risk factors for sleep-disordered breathing in pregnancy. Thorax2014; 69: 371–377.
71.
FaccoFLParkerCBReddyUM, et al.Association between sleep-disordered breathing and hypertensive disorders of pregnancy and gestational diabetes Mellitus. Obstet Gynecol2017; 129: 31–41.
72.
JonesDWFerdinandKCTalerSJ, et al.2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol2025; 86: 1567–1678.
